Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 5, 2024
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
Read more at globenewswire.com
